Boston Scientific Picks Next Lead Independent Director And Keeps Performance-Based Bonus Structure

Edward J. Ludwig will stay on the board, while approved incentive plans retain cash bonuses of up to 225% of target.

Share
Boston Scientific Picks Next Lead Independent Director And Keeps Performance-Based Bonus Structure

Boston Scientific, which makes devices used to diagnose and treat disease, picked its next lead independent director Tuesday and approved incentive plans substantially similar to its 2026 programs. David S. Wichmann will succeed Edward J. Ludwig, who will keep his board seat, the company said in an SEC filing.

Wichmann Takes Over In January

Wichmann will become lead independent director on January 1, 2027. He has been a Boston Scientific director since 2021 and chairs the audit committee, while also serving on the risk, science and technology committee.

Ludwig has held the lead independent director position since 2016.

Boston Scientific sells medical devices mainly to hospitals, physicians and other health care providers worldwide. International markets accounted for 36% of its global net sales in 2025, with its markets including the United States, Japan and China.

Cash Bonuses Have A Quality Check

The 2027 cash incentive plan covers eligible employees, including qualifying named executive officers. Company-wide global sales and adjusted earnings per share determine a bonus-pool distribution rate ranging from 0% to 150%.

Managers apply a separate individual performance factor, also ranging from 0% to 150%. An employee's final bonus can reach 225% of target, the same maximum available in prior plan years.

The plan also allows an additional bonus pool capped at 10% of participants' total target bonuses. The board can reduce the distribution rate based on quality objectives and quality-system performance, and retains authority to modify, suspend or end the plan.

Stock Awards Track Returns And Sales

Both executive stock programs measure performance from January 1, 2027 through December 31, 2029. Each allows awards ranging from 0% to 200% of a participant's target.

One compares Boston Scientific's total shareholder return with that of other S&P 500 Healthcare Index companies. The other compares sales growth with the company's financial plan, stripping out currency fluctuations and certain purchases and sales of businesses where a full comparable sales period is unavailable.

The awards take the form of restricted stock units and require both performance and payment-eligibility conditions to be met. Retirement before January 1, 2028 results in full forfeiture under both programs, with specified exceptions applying for changes of control, retirement, death or disability.

Certain executives' cash and stock awards are subject to recovery policies. Those include discretionary recovery for misconduct or gross neglect of duty that materially violates company policy and significantly harms the company, alongside its Dodd-Frank clawback policy.

The leadership handoff starts January 1, 2027, when the new cash bonus performance year and both stock-award measurement periods also begin.

Sources

More on Boston Scientific

All Boston Scientific (BSX) coverage →